Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints

E-ISSN： 1873-4286|24|17|1879-1886

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.24, Iss.17, 2018-05, pp. : 1879-1886

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors

By Holst Jens Juul

Expert Opinion on Emerging Drugs, Vol. 9, Iss. 1, 2004-05 ,pp. : 155-166

Informa Healthcare

Access to resources Recommend Favorite

Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors

By Ahrén Bo

European Diabetes Nursing, Vol. 10, Iss. 1, 2013-03 ,pp. : 31-36

Blackwell Publishing

Access to resources Recommend Favorite

Emerging GLP-1 receptor agonists

By Lund Asger Knop Filip K Vilsbøll Tina

Expert Opinion on Emerging Drugs, Vol. 16, Iss. 4, 2011-12 ,pp. : 607-618

Informa Healthcare

Access to resources Recommend Favorite

Novel GLP-1 receptor agonists for diabetes

By Garber Alan J

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 1, 2012-01 ,pp. : 45-57

Informa Healthcare

Access to resources Recommend Favorite

A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes

By Montanya Eduard

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 10, 2012-07 ,pp. : 1451-1467

Informa Healthcare

Access to resources Recommend Favorite